Abstract
Overview
Introduction
Mainly affecting women, fibromyalgia syndrome affects six million people in
the US alone. This relatively common yet poorly understood syndrome is
characterized by widespread muscle pain and fatigue and remains substantially
underserved by the medical profession and the pharmaceutical industry.
Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan
or Europe.
Scope
- Analysis of the patient potential, main unmet needs, and clinical trial
design in fibromyalgia, with an estimation of market size
- Insight into current treatment controversies, including referral and
prescribing patterns across the seven major markets
- Detailed profiles of Cymbalta, Lyrica, and milnacipran for use in
fibromyalgia, with indication-specific sales forecasts of these drugs to 2016
- Discussion of key fibromyalgia market drivers, such as strategies that
improve public awareness and physician education
Report Highlights
Following FDA approvals, Datamonitor foresees a dramatic rise in market value
resulting from an upsurge in diagnosis and treatment rates. Estimated at $367m
in 2006 in the US and 5EU, the market is forecast to grow to $1.7 billion in
2016.
Commercial success of new fibromyalgia brands will encourage other companies
to consider investment, and will see the R&D pipeline for new therapies
increase over the coming years. A defined regulatory pathway will also attract
future investors.
Polypharmacotherapy will become commonplace in fibromyalgia management and
Lyrica with Cymbalta will be a popular combination. This is good news for
Lilly and Pfizer as it will effectively expand their market by reducing
competition.
Reasons to Purchase
- Quantify the future market size in order to weigh up the risk of investing
in fibromyalgia or to validate internal forecasts for pipeline products
- Gain insight into opinion leaders' thoughts on the major opportunities and
challenges facing the fibromyalgia market
- Assess the six major market (US and 5EU) sales forecasts of key late-stage
pipeline drugs to 2016; and examine their clinical and commercial potential
| 
View Cart
